Creutzig A - Search Results

1

[Comparison of 50 mg and 900 mg/day acetylsalicylic acid for prevention of recurrence after percutaneous transluminal angioplasty of the lower extremities: results of the LARA study].

Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, Frölich JC, Avenarius HJ, Hecker H, Alexander K. Ranke C, et al. Among authors: creutzig a. Vasa Suppl. 1992;35:42-5. Vasa Suppl. 1992. PMID: 1481057 Clinical Trial. German. No abstract available.

2

[Acetylsalicylic acid therapy in vascular diseases].

Ranke C, Creutzig A, Alexander K. Ranke C, et al. Among authors: creutzig a. Dtsch Med Wochenschr. 1988 Jul 15;113(28-29):1158-61. doi: 10.1055/s-2008-1067788. Dtsch Med Wochenschr. 1988. PMID: 3292193 Review. German. No abstract available.

3

Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease.

Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, Bode-Böger S, Frölich J, Avenarius HJ, Hecker H, ALexander K. Ranke C, et al. Among authors: creutzig a. Clin Investig. 1994 Sep;72(9):673-80. doi: 10.1007/BF00212985. Clin Investig. 1994. PMID: 7849445 Clinical Trial.

4

[Acetylsalicylic acid in arterial circulatory disorders. Which dosage in which indication?].

Ranke C, Creutzig A, Alexander K. Ranke C, et al. Among authors: creutzig a. Dtsch Med Wochenschr. 1994 Jun 3;119(22):815-21. doi: 10.1055/s-2008-1058766. Dtsch Med Wochenschr. 1994. PMID: 8205945 Review. German. No abstract available.

5

[Dose-dependent side effects of acetylsalicylic acid therapy. Results of a prospective randomized clinical study in patients with peripheral arterial occlusive disease].

Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, Bode-Böger S, Frölich J, Avenarius HJ, Hecker H, Alexander K. Ranke C, et al. Among authors: creutzig a. Med Klin (Munich). 1993 Oct 15;88(10):571-6. Med Klin (Munich). 1993. PMID: 8272018 Clinical Trial. German.

6

[Dose-dependent inhibition of plaque growth in the carotid artery by acetylsalicylic acid].

Ranke C, Creutzig A, Hecker H, Alexander K. Ranke C, et al. Among authors: creutzig a. Vasa Suppl. 1992;35:143-6. Vasa Suppl. 1992. PMID: 1481021 Clinical Trial. German. No abstract available.

7

[The reproducibility of transcutaneous oxygen pressure by continuous registration].

Creutzig A, Caspary L, Alexander K. Creutzig A, et al. Vasa Suppl. 1992;35:32-3. Vasa Suppl. 1992. PMID: 1481053 German. No abstract available.

8

[Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].

Creutzig A, Caspary L, Alexander K. Creutzig A, et al. Vasa Suppl. 1992;35:36-8. Vasa Suppl. 1992. PMID: 1481055 Clinical Trial. German. No abstract available.

9

[Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].

Thum J, Caspary L, Creutzig A, Alexander K. Thum J, et al. Among authors: creutzig a. Vasa Suppl. 1992;35:39-41. Vasa Suppl. 1992. PMID: 1481056 German. No abstract available.

10

[Correlation of hemoglobin oxygen saturation with ankle blood pressure in patients with peripheral arterial occlusive disease].

Thum J, Caspary L, Creutzig A, Alexander K. Thum J, et al. Among authors: creutzig a. Vasa Suppl. 1992;35:46-9. Vasa Suppl. 1992. PMID: 1481058 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters